| Drug Name | Rinvoq (upadacitinib) |
|---|---|
| Drug Class | |
| Risk minimization type |
Patient Card
|
| Specialty (Theraputic area) |
Rheumatology
|
| Risk |
safety information about: • Serious and opportunistic infections, including tuberculosis (TB) • Herpes zoster – varicella zoster viral reactivation • Potential risk of birth defects if upadacitinib is taken during pregnancy • Potential risk of major cardiovascular events • Potential risk of venous thromboembolic events |
| Patient card |
|
| Health care provider guide |
|